Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial

Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial

Post, C.C.B.
Boer, S.M. de
Powell, M.E.
Mileshkin, L.
Katsaros, D.
Bessette, P.
Haie-Meder, C.
Ottevanger, N.P.B.
Ledermann, J.A.
Khaw, P.
D'Amico, R.
Fyles, A.
Baron, M.H.
Kitchener, H.C.
Nijman, H.W.
Lutgens, L.C.H.W.
Brooks, S.
Jurgenliemk-Schulz, I.M.
Feeney, A.
Goss, G.
Fossati, R.
Ghatage, P.
Leary, A.
, V. do
Lissoni, A.A.
McCormack, M.
Nout, R.A.
Verhoeven-Adema, K.W.
Smit, V.T.H.B.M.
Putter, H.
Creutzberg, C.L.

March 2021

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

Adjuvant Chemotherapy for Endometrial Cancer Unproven

Creutzberg, C.L.

October 2010

High-risk endometrial cancer (EC), only 15% of all EC, mainly affects elderly women, often with sign...

PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

van den Heerik, Anne Sophie V M
Horeweg, Nanda
Nout, Remi A
Lutgens, Ludy C H W
van der Steen-Banasik, Elzbieta M
Westerveld, G Henrike
van den Berg, Hetty A
Slot, Annerie
Koppe, Friederike L A
Kommoss, Stefan
Mens, Jan Willem M
Nowee, Marlies E
Bijmolt, Stefan
Cibula, David
Stam, Tanja C
Jurgenliemk-Schulz, Ina M
Snyers, An
Hamann, Moritz
Zwanenburg, Aleida G
Coen, Veronique L M A
Vandecasteele, Katrien
Gillham, Charles
Chargari, Cyrus
Verhoeven-Adema, Karen W
Putter, Hein
van den Hout, Wilbert B
Wortman, Bastiaan G
Nijman, Hans W
Bosse, Tjalling
Creutzberg, Carien L

December 2020

BACKGROUND: Vaginal brachytherapy is currently recommended as adjuvant treatment in patients with hi...

Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial

Wortman, B.G.
Bosse, T.
Nout, R.A.
Lutgens, L.C.H.W.
van der Steen-Banasik, E.M.
Westerveld, H.
van den Berg, H.
Slot, A.
De Winter, K.A.J.
Verhoeven-Adema, K.W.
Smit, V.T.H.B.M.
Creutzberg, C.L.

October 2018

Objective. The Post-Operative Radiation Therapy in Endometrial Carcinoma (PORTEC)-4a trial is a rand...

Molecular risk stratification to direct therapy in endometrial cancer: ready for the clinic?

Creutzberg, C.L.
Bosse, T.

May 2018

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy.

Heerik, A.S.V.M. van den
Horeweg, N.
Boer, S.M. de
Bosse, T.
Creutzberg, C.L.

August 2020

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer

Wortman, B.G.
Astreinidou, E.
Laman, M.S.
Steen-Banasik, E.M. van der
Lutgens, L.C.H.W.
Westerveld, H.
Koppe, F.
Slot, A.
Berg, H.A. van den
Nowee, M.E.
Bijmolt, S.
Stam, T.C.
Zwanenburg, A.G.
Mens, J.W.M.
Jurgenliemk-Schulz, I.M.
Snyers, A.
Gillham, C.M.
Weidner, N.
Kommoss, S.
Vandecasteele, K.
Tomancova, V.
Creutzberg, C.L.
Nout, R.A.
PORTEC Study Grp

February 2021

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial

Boer, S.M. de
Powell, M.E.
Mileshkin, L.
Katsaros, D.
Bessette, P.
Haie-Meder, C.
Ottevanger, P.B.
Ledermann, J.A.
Khaw, P.
Colombo, A.
Fyles, A.
Baron, M.H.
Kitchener, H.C.
Nijman, H.W.
Kruitwagen, R.F.
Nout, R.A.
Verhoeven-Adema, K.W.
Smit, V.T.
Putter, H.
Creutzberg, C.L.
PORTEC Study Grp

January 2016

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

Radiotherapy for endometrial cancer: improved patient selection, techniques and outcomes

Wortman, B.G.

December 2022

Endometrial cancer (EC) is the most common gynaecological cancer in developed countries. Standard tr...

PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.

Heerik, A.S.V.M. van den
Horeweg, N.
Nout, R.A.
Lutgens, L.C.H.W.
Steen-banasik, E.M. van der
Westerveld, G.H.
Berg, H.A. van den
Slot, A.
Koppe, F.L.A.
Kommoss, S.
Mens, J.W.M.
Nowee, M.E.
Bijmolt, S.
Cibula, D.
Stam, T.C.
Jurgenliemk-Schulz, I.M.
Snyers, A.
Hamann, M.
Zwanenburg, A.G.
Coen, V.L.M.A.
Vandecasteele, K.
Gillham, C.
Chargari, C.
Verhoeven-Adema, K.W.
Putter, H.
Hout, W.B. van den
Wortman, B.G.
Nijman, H.W.
Bosse, T.
Creutzberg, C.L.

August 2020

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy

Heerik, A.S.V.M. van den
Horeweg, N.
Boer, S.M. de
Bosse, T.
Creutzberg, C.L.

April 2021

Endometrial cancer is primarily treated with surgery. Adjuvant treatment strategies for endometrial ...

Clinicopathological Characterization of Endometrial Carcinomas with More Than One Molecular Classifying Feature

Leon, A.
McAlpine, J.N.
Nout, R.
McConechy, M.K.
Ganesan, R.
Matias-Guiu, X.
Oliva, E.
Harrison, B.T.
Soslow, R.
Church, D.
Gilks, C.B.
Bosse, T.

March 2018

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

PORTEC-4a:international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

van den Heerik, Anne Sophie V. M.
Horeweg, Nanda
Nout, Remi A.
Lutgens, Ludy C. H. W.
van der Steen-banasik, Elzbieta M.
Westerveld, G. Henrike
van den Berg, Hetty A.
Slot, Annerie
Koppe, Friederike L. A.
Kommoss, Stefan
Mens, Jan Willem M.
Nowee, Marlies E.
Bijmolt, Stefan
Cibula, David
Stam, Tanja C.
Jurgenliemk-Schulz, Ina M.
Snyers, An
Hamann, Moritz
Zwanenburg, Aleida G.
Coen, Veronique L. M. A.
Vandecasteele, Katrien
Gillham, Charles
Chargari, Cyrus
Verhoeven-Adema, Karen W.
Putter, Hein
van den Hout, Wilbert B.
Wortman, Bastiaan G.
Nijman, Hans W.
Bosse, Tjalling
Creutzberg, Carien L.

December 2020

BackgroundVaginal brachytherapy is currently recommended as adjuvant treatment in patients with high...

Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial

Blinman, P.
Mileshkin, L.
Khaw, P.
Goss, G.
Johnson, C.
Capp, A.
Brooks, S.
Wain, G.
Kolodziej, I.
Veillard, A.S.
O'Connell, R.
Creutzberg, C.L.
Stockler, M.R.
ANZGOG
PORTEC Grp

November 2016

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative

Auguste, A.
Genestie, C.
Bruyn, M. de
Adam, J.
Formal, A. le
Drusch, F.
Pautier, P.
Crosbie, E.J.
MacKay, H.
Kitchener, H.C.
Powell, M.
Pollock, P.M.
Mileshkin, L.
Edmondson, R.J.
Nout, R.
Nijman, H.W.
Creutzberg, C.L.
Bosse, T.
Leary, A.

December 2018

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial

Post, C.C.B.
Boer, S.M. de
Powell, M.E.
Mileshkin, L.
Katsaros, D.
Bessette, P.
Haie-Meder, C.
Ottevanger, N.P.B.
Ledermann, J.A.
Khaw, P.
D'Amico, R.
Fyles, A.
Baron, M.H.
Kitchener, H.C.
Nijman, H.W.
Lutgens, L.C.H.W.
Brooks, S.
Jurgenliemk-Schulz, I.M.
Feeney, A.
Goss, G.
Fossati, R.
Ghatage, P.
Leary, A.
, V. do
Lissoni, A.A.
McCormack, M.
Nout, R.A.
Verhoeven-Adema, K.W.
Smit, V.T.H.B.M.
Putter, H.
Creutzberg, C.L.

March 2021

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

Adjuvant Chemotherapy for Endometrial Cancer Unproven

Creutzberg, C.L.

October 2010

High-risk endometrial cancer (EC), only 15% of all EC, mainly affects elderly women, often with sign...

PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

van den Heerik, Anne Sophie V M
Horeweg, Nanda
Nout, Remi A
Lutgens, Ludy C H W
van der Steen-Banasik, Elzbieta M
Westerveld, G Henrike
van den Berg, Hetty A
Slot, Annerie
Koppe, Friederike L A
Kommoss, Stefan
Mens, Jan Willem M
Nowee, Marlies E
Bijmolt, Stefan
Cibula, David
Stam, Tanja C
Jurgenliemk-Schulz, Ina M
Snyers, An
Hamann, Moritz
Zwanenburg, Aleida G
Coen, Veronique L M A
Vandecasteele, Katrien
Gillham, Charles
Chargari, Cyrus
Verhoeven-Adema, Karen W
Putter, Hein
van den Hout, Wilbert B
Wortman, Bastiaan G
Nijman, Hans W
Bosse, Tjalling
Creutzberg, Carien L

December 2020

BACKGROUND: Vaginal brachytherapy is currently recommended as adjuvant treatment in patients with hi...

Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial

Wortman, B.G.
Bosse, T.
Nout, R.A.
Lutgens, L.C.H.W.
van der Steen-Banasik, E.M.
Westerveld, H.
van den Berg, H.
Slot, A.
De Winter, K.A.J.
Verhoeven-Adema, K.W.
Smit, V.T.H.B.M.
Creutzberg, C.L.

October 2018

Objective. The Post-Operative Radiation Therapy in Endometrial Carcinoma (PORTEC)-4a trial is a rand...

Molecular risk stratification to direct therapy in endometrial cancer: ready for the clinic?

Creutzberg, C.L.
Bosse, T.

May 2018

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy.

Heerik, A.S.V.M. van den
Horeweg, N.
Boer, S.M. de
Bosse, T.
Creutzberg, C.L.

August 2020

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer

Wortman, B.G.
Astreinidou, E.
Laman, M.S.
Steen-Banasik, E.M. van der
Lutgens, L.C.H.W.
Westerveld, H.
Koppe, F.
Slot, A.
Berg, H.A. van den
Nowee, M.E.
Bijmolt, S.
Stam, T.C.
Zwanenburg, A.G.
Mens, J.W.M.
Jurgenliemk-Schulz, I.M.
Snyers, A.
Gillham, C.M.
Weidner, N.
Kommoss, S.
Vandecasteele, K.
Tomancova, V.
Creutzberg, C.L.
Nout, R.A.
PORTEC Study Grp

February 2021

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial

Boer, S.M. de
Powell, M.E.
Mileshkin, L.
Katsaros, D.
Bessette, P.
Haie-Meder, C.
Ottevanger, P.B.
Ledermann, J.A.
Khaw, P.
Colombo, A.
Fyles, A.
Baron, M.H.
Kitchener, H.C.
Nijman, H.W.
Kruitwagen, R.F.
Nout, R.A.
Verhoeven-Adema, K.W.
Smit, V.T.
Putter, H.
Creutzberg, C.L.
PORTEC Study Grp

January 2016

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

Radiotherapy for endometrial cancer: improved patient selection, techniques and outcomes

Wortman, B.G.

December 2022

Endometrial cancer (EC) is the most common gynaecological cancer in developed countries. Standard tr...

PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.

Heerik, A.S.V.M. van den
Horeweg, N.
Nout, R.A.
Lutgens, L.C.H.W.
Steen-banasik, E.M. van der
Westerveld, G.H.
Berg, H.A. van den
Slot, A.
Koppe, F.L.A.
Kommoss, S.
Mens, J.W.M.
Nowee, M.E.
Bijmolt, S.
Cibula, D.
Stam, T.C.
Jurgenliemk-Schulz, I.M.
Snyers, A.
Hamann, M.
Zwanenburg, A.G.
Coen, V.L.M.A.
Vandecasteele, K.
Gillham, C.
Chargari, C.
Verhoeven-Adema, K.W.
Putter, H.
Hout, W.B. van den
Wortman, B.G.
Nijman, H.W.
Bosse, T.
Creutzberg, C.L.

August 2020

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy

Heerik, A.S.V.M. van den
Horeweg, N.
Boer, S.M. de
Bosse, T.
Creutzberg, C.L.

April 2021

Endometrial cancer is primarily treated with surgery. Adjuvant treatment strategies for endometrial ...

Clinicopathological Characterization of Endometrial Carcinomas with More Than One Molecular Classifying Feature

Leon, A.
McAlpine, J.N.
Nout, R.
McConechy, M.K.
Ganesan, R.
Matias-Guiu, X.
Oliva, E.
Harrison, B.T.
Soslow, R.
Church, D.
Gilks, C.B.
Bosse, T.

March 2018

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

PORTEC-4a:international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

van den Heerik, Anne Sophie V. M.
Horeweg, Nanda
Nout, Remi A.
Lutgens, Ludy C. H. W.
van der Steen-banasik, Elzbieta M.
Westerveld, G. Henrike
van den Berg, Hetty A.
Slot, Annerie
Koppe, Friederike L. A.
Kommoss, Stefan
Mens, Jan Willem M.
Nowee, Marlies E.
Bijmolt, Stefan
Cibula, David
Stam, Tanja C.
Jurgenliemk-Schulz, Ina M.
Snyers, An
Hamann, Moritz
Zwanenburg, Aleida G.
Coen, Veronique L. M. A.
Vandecasteele, Katrien
Gillham, Charles
Chargari, Cyrus
Verhoeven-Adema, Karen W.
Putter, Hein
van den Hout, Wilbert B.
Wortman, Bastiaan G.
Nijman, Hans W.
Bosse, Tjalling
Creutzberg, Carien L.

December 2020

BackgroundVaginal brachytherapy is currently recommended as adjuvant treatment in patients with high...

Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial

Blinman, P.
Mileshkin, L.
Khaw, P.
Goss, G.
Johnson, C.
Capp, A.
Brooks, S.
Wain, G.
Kolodziej, I.
Veillard, A.S.
O'Connell, R.
Creutzberg, C.L.
Stockler, M.R.
ANZGOG
PORTEC Grp

November 2016

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative

Auguste, A.
Genestie, C.
Bruyn, M. de
Adam, J.
Formal, A. le
Drusch, F.
Pautier, P.
Crosbie, E.J.
MacKay, H.
Kitchener, H.C.
Powell, M.
Pollock, P.M.
Mileshkin, L.
Edmondson, R.J.
Nout, R.
Nijman, H.W.
Creutzberg, C.L.
Bosse, T.
Leary, A.

December 2018

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial

Post, C.C.B.
Boer, S.M. de
Powell, M.E.
Mileshkin, L.
Katsaros, D.
Bessette, P.
Haie-Meder, C.
Ottevanger, N.P.B.
Ledermann, J.A.
Khaw, P.
D'Amico, R.
Fyles, A.
Baron, M.H.
Kitchener, H.C.
Nijman, H.W.
Lutgens, L.C.H.W.
Brooks, S.
Jurgenliemk-Schulz, I.M.
Feeney, A.
Goss, G.
Fossati, R.
Ghatage, P.
Leary, A.
, V. do
Lissoni, A.A.
McCormack, M.
Nout, R.A.
Verhoeven-Adema, K.W.
Smit, V.T.H.B.M.
Putter, H.
Creutzberg, C.L.

March 2021

Biological, physical and clinical aspects of cancer treatment with ionising radiatio

Adjuvant Chemotherapy for Endometrial Cancer Unproven

Creutzberg, C.L.

October 2010

High-risk endometrial cancer (EC), only 15% of all EC, mainly affects elderly women, often with sign...

PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

van den Heerik, Anne Sophie V M
Horeweg, Nanda
Nout, Remi A
Lutgens, Ludy C H W
van der Steen-Banasik, Elzbieta M
Westerveld, G Henrike
van den Berg, Hetty A
Slot, Annerie
Koppe, Friederike L A
Kommoss, Stefan
Mens, Jan Willem M
Nowee, Marlies E
Bijmolt, Stefan
Cibula, David
Stam, Tanja C
Jurgenliemk-Schulz, Ina M
Snyers, An
Hamann, Moritz
Zwanenburg, Aleida G
Coen, Veronique L M A
Vandecasteele, Katrien
Gillham, Charles
Chargari, Cyrus
Verhoeven-Adema, Karen W
Putter, Hein
van den Hout, Wilbert B
Wortman, Bastiaan G
Nijman, Hans W
Bosse, Tjalling
Creutzberg, Carien L

December 2020

BACKGROUND: Vaginal brachytherapy is currently recommended as adjuvant treatment in patients with hi...

Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial

Abstract

Extracted data

Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial

Abstract

Extracted data

Related items

Related items